Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EPS (Basic) (2023 - 2025)

Historic EPS (Basic) for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$3.59.

  • Tonix Pharmaceuticals Holding's EPS (Basic) rose 8417.11% to -$3.59 in Q3 2025 from the same period last year, while for Sep 2025 it was $279.28, marking a year-over-year increase of 10163.74%. This contributed to the annual value of -$176.6 for FY2024, which is 9880.03% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported EPS (Basic) of -$3.59 as of Q3 2025, which was up 8417.11% from -$3.86 recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's EPS (Basic) ranged from a high of -$2.84 in Q1 2025 and a low of -$14576.8 during Q4 2023
  • Moreover, its 3-year median value for EPS (Basic) was -$30.02 (2024), whereas its average is -$1903.9.
  • In the last 5 years, Tonix Pharmaceuticals Holding's EPS (Basic) skyrocketed by 4128.92% in 2024 and then surged by 9979.9% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's EPS (Basic) stood at -$14576.8 in 2023, then soared by 99.79% to -$30.02 in 2024, then surged by 88.04% to -$3.59 in 2025.
  • Its EPS (Basic) was -$3.59 in Q3 2025, compared to -$3.86 in Q2 2025 and -$2.84 in Q1 2025.